Achieve Life Sciences AI Stock Analysis
Want to see QUIT full AI Analyst Report?
Achieve Life Sciences (QUIT) AI Stock Analysis
Achieve Life Sciences
(NASDAQ:QUIT)
The score is primarily weighed down by weak financial performance (no revenue, widening losses, ongoing cash burn) and balance-sheet strain (negative equity), which elevate financing/dilution risk. Technicals provide only moderate support with a longer-term uptrend but neutral momentum. Valuation is unattractive on earnings due to a negative P/E, and corporate actions add flexibility but also reinforce dilution concerns.
Achieve Life Sciences (QUIT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $671.36M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.47M
- Price to Earnings (P/E)
- -4.7
- Beta (1Y)
- 2.75
- Revenue Growth
- ―
- EPS Growth
- -0.17%
- Country
- US
- Employees
- 28
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Achieve Life Sciences Business Overview & Revenue Model
Company Description
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Achieve Life Sciences has not established a stable, product-based commercial revenue stream because its lead product candidate is investigational and not confirmed to be approved for sale. Accordingly, t...
Achieve Life Sciences Financial Statement Overview
Summary
Financials are characteristic of a high-risk, development-stage biotech: $0 revenue across periods, materially widening net losses in TTM (~$114M), and persistent negative operating/free cash flow (TTM FCF about -$47M). The balance sheet also weakened with equity turning negative in TTM (about -$14.7M), increasing financing and dilution risk despite relatively modest absolute debt (~$15M).
Income Statement
8Very NegativeBalance Sheet
22NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -57.00K | -228.00K | -229.00K | 0 | 0 | 0 |
| EBITDA | -112.17M | -53.60M | -37.42M | -26.73M | -40.33M | -32.90M |
| Net Income | -111.71M | -54.65M | -39.83M | -29.82M | -42.35M | -33.15M |
Balance Sheet | ||||||
| Total Assets | 206.42M | 41.79M | 38.63M | 19.37M | 29.97M | 47.52M |
| Cash, Cash Equivalents and Short-Term Investments | 201.52M | 36.40M | 34.34M | 15.55M | 24.72M | 43.02M |
| Total Debt | 13.76M | 14.96M | 9.96M | 16.73M | 16.20M | 14.99M |
| Total Liabilities | 25.69M | 20.27M | 17.73M | 20.82M | 21.67M | 19.47M |
| Stockholders Equity | 180.73M | 21.52M | 20.90M | -1.45M | 8.30M | 28.04M |
Cash Flow | ||||||
| Free Cash Flow | -44.09M | -49.47M | -29.77M | -24.50M | -37.57M | -29.44M |
| Operating Cash Flow | -44.04M | -49.47M | -29.77M | -24.48M | -37.57M | -29.44M |
| Investing Cash Flow | -124.48M | 6.11M | -21.58M | -21.00K | 0 | 0 |
| Financing Cash Flow | 196.32M | 51.53M | 48.53M | 15.28M | 19.32M | 36.61M |
Achieve Life Sciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QUIT, the sentiment is Negative. The current price of 6.45 is below the 20-day moving average (MA) of 6.67, below the 50-day MA of 7.22, and above the 200-day MA of 5.69, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 43.19 is Neutral, neither overbought nor oversold. The STOCH value of 34.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QUIT.
Achieve Life Sciences Risk Analysis
Achieve Life Sciences disclosed 68 risk factors in its most recent earnings report. Achieve Life Sciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAchieve Life Sciences Peers Comparison
Overall Rating
NERV54Neutral
OVID52Neutral- QUIT47Neutral
AVXL46Neutral
ACIU45Neutral
VNDA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NERV | 54Neutral | $124.09M | -0.10 | 167.68% | ― | ― | -1306.84% |
| OVID | 52Neutral | $546.83M | -6.78 | -23.38% | ― | -78.05% | 63.85% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| QUIT | 47Neutral | $658.58M | -4.67 | -225.39% | ― | ― | -0.17% |
| AVXL | 46Neutral | $104.75M | -7.21 | -11.43% | ― | ― | 73.28% |
| ACIU | 45Neutral | $233.06M | -4.69 | -104.05% | ― | 384.77% | 38.30% |
| VNDA | 39Underperform | $246.72M | -0.90 | -106.94% | ― | 8.11% | -222.50% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| QUIT | Achieve Life Sciences | 6.45 | 1.87 | 40.83% | |
| VNDA | Vanda Pharmaceuticals | 4.15 | -0.19 | -4.38% | |
| NERV | Minerva Neurosciences | 2.56 | -1.29 | -33.51% | |
| AVXL | Anavex Life Sciences | 1.06 | -4.63 | -81.37% | |
| ACIU | AC Immune | 2.26 | -0.97 | -30.03% | |
| OVID | Ovid Therapeutics | 2.78 | 1.58 | 131.67% |
Achieve Life Sciences Corporate Events
Achieve Life Sciences Appoints Benjamin Halladay as CFO
PositiveOn October 1, 2026, Achieve Life Sciences announced that its Board appointed Benjamin Halladay as Chief Financial Officer and principal financial officer, effective October 5, 2026, succeeding outgoing CFO Mark Oki. Halladay, a Certified Public Accou...
Achieve Life Sciences Launches $150M ATM Equity Program
PositiveOn August 14, 2026, Achieve Life Sciences entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market equity offering program of up to $150 million in common stock. Under the agreement, Jefferies will act as sales agen...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 02, 2026